Sponsor Pipeline

Calcilytix Therapeutics, Inc., a BridgeBio company Clinical Trial Pipeline

Data updated daily from ClinicalTrials.gov — last refresh 2026-08-16
3
Active Trials
1
Recruiting
2
Phase 3
Active Trials by Phase
Phase 3
1
Phase 2/3
1
Not specified
1
Active Trials
NCT IDTitleConditionStatus
Phase 3
NCT05680818 Efficacy and Safety of Encaleret Compared to Standard of Care in Participants With ADH1 Autosomal Dominant Hypocalcemia (ADH) Active, Not Recruiting
Phase 2/3
NCT07080385 Pharmacokinetics, Efficacy, and Safety of Encaleret in Pediatric Participants With… Autosomal Dominant Hypocalcemia Type 1 (ADH1) Recruiting
Not specified
NCT05227287 ADH1 and ADH2 Disease Monitoring Study (DMS) Autosomal Dominant Hypocalcemia Active, Not Recruiting
Get alerts when Calcilytix Therapeutics, Inc., a BridgeBio company's trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free